Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Company Overview - Rezolute, Inc. is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI) [3] - The company's antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and real-world cases for both congenital and tumor HI [3] Upcoming Events - Management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, taking place on February 11-12, 2026, in New York [1] - One-on-one investor meetings will be held throughout the conference, and interested investors can contact their Guggenheim representative to schedule a meeting with the management team [2]